MyoKi

MyoKi
Product Description

MyoKi is an oral anti-myostatin peptide designed to support muscle mass and strength, enabling safe and effective muscle health management across all age groups.

Product OverviewMyoKi is a peptide-based nutraceutical developed to support muscle preservation and functional performance through the selective inhibition of myostatin, a key regulator of muscle atrophy. Formulated as a once-daily oral supplement, it is positioned as a complementary solution to GLP-1-based therapies during weight management. MyoKi is designed for aging populations, weight-management users, and active consumers. In February 2025, it completed the U.S. FDA New Dietary Ingredient (NDI) notification, becoming the first myostatin-inhibiting synthetic peptide to receive this designation.

Caregen Co.,Ltd.

  • Country/Region:
    Korea, Republic Of
  • Founded:
    2001
  • On CPHI since:
    2016
  • Certificates:
    3
  • Employees:
    100 - 249
Company types
Biopharmaceutical company
Consumer Goods
Distributor/Import Export
Drug delivery device Supplier/Manufacturer
Manufacturer/Innovator
OTC
Other
Primary activities
API Producer
Biopharmaceutical
Cosmeceuticals
Cosmetic Ingredients
Nutraceuticals
OTC
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
Specifications
  • Selling Points
    Human Clinical Results
    • Skeletal Muscle Mass: +2.52%
    • Lean Muscle Mass: +2.56%
    • Grip Strength: +5.6-6.2%
    • 6-Meter Walk Test performance: +12.4%
    • Biomarker validation: Increased anabolic signals and decreased catabolic markers

Caregen Co.,Ltd.

  • Country/Region:
    Korea, Republic Of
  • Founded:
    2001
  • On CPHI since:
    2016
  • Certificates:
    3
  • Employees:
    100 - 249
Company types
Biopharmaceutical company
Consumer Goods
Distributor/Import Export
Drug delivery device Supplier/Manufacturer
Manufacturer/Innovator
OTC
Other
Primary activities
API Producer
Biopharmaceutical
Cosmeceuticals
Cosmetic Ingredients
Nutraceuticals
OTC
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)

More Products from Caregen Co.,Ltd. (5)

  • CG-P5

    Product CG-P5

    First-in-Class VEGFR2-Inhibiting Peptide Eye Drop for Wet Age-Related Macular Degeneration

    Product Overview: A New Standard for Non-Invasive Retinal Therapy
    CG-P5 is a first-in-class VEGFR2-inhibiting biomimetic peptide developed as a topical eye drop for the treatment of wet age-related m...
  • CG-T1

    Product CG-T1

    Peptide-Based Topical Therapeutic for Dry Eye Disease (DED)

    Product Overview: A Restorative Approach to Dry Eye Disease

    CG-T1 is a next-generation peptide-based topical therapy for dry eye disease, advancing toward Phase 2 clinical development in the United States following successfu...
  • Korglutide

    Product Korglutide

    Korglutide is a next-generation oral dual GLP-1R/IGF-1R peptide designed to support safe and muscle-preserving weight loss as a non-injectable nutraceutical alternative.
    Product Overview
    Korglutide is a synthetic dual GLP-1R and IGF-1R agonist peptide developed by Caregen for weight management and ...
  • ProGsterol

    Product ProGsterol

    ProGsterol is an oral peptide-based nutraceutical designed to improve insulin receptor sensitivity and regulate glucose metabolism, supporting overall metabolic balance.
    Product Overview
    ProGsterol is a peptide-based nutraceutical developed by Caregen for metabolic disorders, including insulin re...
  • CG-Luxidase

    Product CG-Luxidase

    CG-Luxidase is a proprietary peptide-based delivery platform designed to enhance the penetration and distribution of active compounds by transiently modulating the hyaluronic acid (HA) network within the extracellular matrix (ECM).

    As a water-soluble synthetic decapeptide (INCI: Decapeptide-51),...

Caregen Co.,Ltd. resources (1)